Reagents for Astatination of Biomolecules. 4. Comparison of Maleimido-closo-Decaborate(2-) and meta-[211At]Astatobenzoate Conjugates for Labeling anti-CD45 Antibodies with [211At]Astatine
Authors:
- 4 September 2009
- journal article
- research article
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 20 (10) , 1983-1991
Abstract
An investigation was conducted to compare the in vivo tissue distribution of a rat antimurine CD45 monoclonal antibody (30F11) and an irrelevant mAbs (CA12.10C12) labeled with 211At using two different labeling methods. In the investigation, the mAbs were also labeled with 125I to assess the in vivo stability of the labeling methods toward deastatination. One labeling method employed N-hydroxysuccinimidyl meta-[211At]astatobenzoate, [211At]1c, and N-hydroxysuccinimidyl meta-[125I]iodobenzoate, [125I]1b, in conjugation reactions to obtain the radiolabeled mAbs. The other labeling method involved conjugation of a maleimido-closo-decaborate(2-) derivative, 2, with sulfhydryl groups on the mAbs, followed by labeling of the mAb-2 conjugates using Na[211At]At or Na[125I]I and chloramine-T. Concentrations of the 211At/125I pair of radiolabeled mAbs in selected tissues were examined in BALB/c mice at 1, 4, and 24 h post injection (pi). The co-injected anti-CD45 mAb, 30F11, labeled with [125I]1b and [211At]1c targeted the CD45-bearing cells in the spleen with the percent injected dose (%ID) of 125I in that tissue being 13.31 ± 0.78; 17.43 ± 2.56; 5.23 ± 0.50; and 211At being 6.56 ± 0.40; 10.14 ± 1.49; 7.52 ± 0.79 at 1, 4, and 24 h pi (respectively). However, better targeting (or retention) of the 125I and 211At was obtained for 30F11 conjugated with the closo-decaborate(2-), 2. The %ID in the spleen of 125I (i.e., [125I]30F11-2) being 21.15 ± 1.33; 22.22 ± 1.95; 12.41 ± 0.75; and 211At (i.e., [211At]30F11-2) being 22.78 ± 1.29; 25.05 ± 2.35; 17.30 ± 1.20 at 1, 4, and 24 h pi (respectively). In contrast, the irrelevant mAb, CA12.10C12, labeled with 125I or 211At by either method had less than 0.8% ID in the spleen at any time point, except for [211At]CA12.10C12-1c, which had 1.62 ± 0.14%ID and 1.21 ± 0.08%ID at 1 and 4 h pi. The higher spleen concentrations in that conjugate appear to be due to in vivo deastatination. Differences in 125I and 211At concentrations in lung, neck, and stomach indicate that the meta-[211At]benzoyl conjugates underwent deastatination, whereas the 211At-labeled closo-decaborate(2-) conjugates were very stable to in vivo deastatination. In summary, using the closo-decaborate(2-) 211At labeling approach resulted in higher concentrations of 211At in target tissue (spleen) and higher stability to in vivo deastatination in this model. These findings, along with the simpler and higher-yielding 211At-labeling method, provide the basis for using the closo-decaborate(2-) labeling reagent, 2, in our continued studies of the application of 211At-labeled mAbs for conditioning in hematopoietic cell transplantation.Keywords
This publication has 32 references indexed in Scilit:
- Biodistributions, Myelosuppression, and Toxicities in Mice Treated with an Anti-CD45 Antibody Labeled with the α-Emitting Radionuclides Bismuth-213 or Astatine-211Cancer Research, 2009
- Clinical Experience with α-Particle–Emitting 211At: Treatment of Recurrent Brain Tumor Patients with 211At-Labeled Chimeric Antitenascin Monoclonal Antibody 81C6Journal of Nuclear Medicine, 2007
- Preparation and in vivo evaluation of novel linkers for 211At labeling of proteinsNuclear Medicine and Biology, 2004
- Biotin Reagents in Antibody Pretargeting. 6. Synthesis and in Vivo Evaluation of Astatinated and Radioiodinated Aryl- andnido-Carboranyl-biotin DerivativesBioconjugate Chemistry, 2004
- Tissue distribution and radiation dosimetry of astatine-211-labeled chimeric 81C6, an α-particle-emitting immunoconjugateNuclear Medicine and Biology, 1997
- Canine Lymphoma: Immunocytochemical Analysis of Fine-needle Aspiration BiopsyVeterinary Pathology, 1996
- Preparation and quality control of 211At‐labelled and 125I‐labelled monoclonal antibodies. Biodistribution in mice carrying human osteosarcoma xenograftsJournal of Labelled Compounds and Radiopharmaceuticals, 1994
- Preparation and evaluation of para-[211At]astatobenzoyl labeled anti-renal cell carcinoma antibody A6H F(ab′)2. In vivo distribution comparison with para-[125I]iodobenzoyl labeled A6H F(ab′)2Nuclear Medicine and Biology, 1993
- Synthesis of radioiodinated N-succinimidyl iodobenzoate: Optimization for use in antibody labellingInternational Journal of Radiation Applications and Instrumentation. Part A. Applied Radiation and Isotopes, 1989
- Astatination of proteins using an N-succinimidyl tri-n-butylstannyl benzoate intermediateInternational Journal of Radiation Applications and Instrumentation. Part A. Applied Radiation and Isotopes, 1988